Pα+ Psychedelic Bulletin #158: Fluence Brings Psychedelic Therapy Training to Ukraine; MindBio’s Microdosing Readout; Biomind’s 5-MeO-DMT Study; and more… Post published:March 6, 2024 Post category:Psychedelic Bulletin/Pα+
Prominent At-Home Ketamine Co. Founder, Juan Pablo Cappello, Sounds Alarm, Withdraws Support for the Practice Post published:March 4, 2024 Post category:Analysis/News/Pα+
The Psychedelic News Feed: Feb 5, 2024 – Mar 3, 2024 Post published:March 4, 2024 Post category:Psychedelic News Feed Archive
Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls Post published:March 1, 2024 Post category:Psychedelic Bulletin/Pα+
Colorado’s Draft Natural Medicine Rules: Full Breakdown & Commentary Post published:February 27, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Colorado’s Draft Natural Medicine Rules: A High-Level Overview Post published:February 27, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Ibogaine Advocates Seek Ohio Opioid Settlement Funds Following Failure in Kentucky Post published:February 23, 2024 Post category:Analysis/News
Pα+ Psychedelic Patent Analysis: A Mebufotenin Melee (Dec ’23 & Jan ’24) Post published:February 22, 2024 Post category:Psychedelic Patent Analysis/Pα+
Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass Post published:February 19, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA Post published:February 16, 2024 Post category:Analysis/Pα+